• Most Popular
  • Most Shared

Watson seeks U.S. approval for generic Lybrel

Thu Mar 13, 2008 4:24pm EDT

Stocks

   

NEW YORK, March 13 (Reuters) - Watson Pharmaceuticals Inc (WPI.N) on Thursday said it had asked U.S. regulators for permission to market its generic form of Wyeth's WYE.N recently launched Lybrel contraceptive.

Stocks

Watson said Wyeth filed suit on Wednesday in Delaware federal court to block Watson from introducing its copycat form of the low-dose oral contraceptive. Watson said the suit, under federal law, automatically will block its generic for up to 30 months.

Cowen and Co has predicted that Lybrel will garner annual sales of $500 million in 2012.

Stocks


More from Reuters

This heart-wrenching picture of a mother and child at an an emergency feeding centre in in Tahoua, Niger, won international acclaim for incorporating beauty, horror and despair. Taken on August 1, 2005 by Finbarr O'Reilly.

Pictures of the Decade

    Pictures
    A customer is served at a counter inside a foreign exchange store displaying a poster of various banknotes including the Chinese yuan or renminbi (RMB) in Hong Kong November 20, 2009. REUTERS/Bobby Yip
    OUTLOOK 2010:

    Be careful what you wish for

    Pressure on China to loosen its grip on the yuan will continue but the U.S. should tread carefully. Here are five world market issues to watch.  Full Article 

    Global Markets
    Aurora, a 20-year-old Beluga whale, swims with her newborn calf after giving birth at the Vancouver Aquarium in Vancouver, British Columbia June 7, 2009. REUTERS/Andy Clark

    365 days for the doomed

    From polar bears to emperor penguins, endangered species will get top online billing in 2010 during the Year of Biodiversity.  Full Article 

    Green Business